<DOC>
	<DOC>NCT00990756</DOC>
	<brief_summary>The purpose of this study is to investigate safety and toleration of multiple inhaled doses as well as the time course of PF-03526299 concentration in the blood following dosing by dry powder inhaler.</brief_summary>
	<brief_title>A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03526299 In Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects and females of nonchildbearing potential between the ages of 21 and 55 years. Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight &gt;50 kg (110 lbs). Subjects who had a normal chest Xray in the previous 6 months prior to Screening Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). A positive urine drug screen. History of regular alcohol consumption exceeding 21 drinks/week for males and 14 drinks/week for females.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>